Literature DB >> 25586848

Lessons from 50 years of curing childhood leukaemia.

Catherine Helen Cole1.   

Abstract

One of the great success stories of modern medicine is undoubtedly the remarkable improvement in outcome for childhood cancer, achieved through the work of the co-operative groups enrolling patients in randomised controlled trials. In 1965, survival was almost zero; now 5-year survival rates exceed 80% in high-income countries. The lessons learned in the care of patients with the most common malignancy in childhood--acute lymphoblastic leukaemia--have been used in all other cancers of childhood and more recently in the management of adults. These lessons can be broadly applied in medical practice, because elements of laboratory science in all branches of pathology, as well as a deep understanding of biochemistry, physiology, pharmacology, genetics and molecular science, run through this story. Far from being a sad area of practice, paediatric haematology and oncology remains the champion of embedded clinical and translational research, diagnosis from bench to bedside and lifelong multidisciplinary management of the child and their family.
© 2015 The Author. Journal of Paediatrics and Child Health © 2015 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Keywords:  haematology; oncology

Mesh:

Substances:

Year:  2015        PMID: 25586848     DOI: 10.1111/jpc.12803

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  2 in total

1.  The challenge of trial design in paediatric rheumatology.

Authors:  Tim Niehues
Journal:  Nat Rev Rheumatol       Date:  2016-04       Impact factor: 20.543

2.  Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study.

Authors:  Eric W Tai; Kevin C Ward; Audrey Bonaventure; David A Siegel; Michel P Coleman
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.